Cullinan Therapeutics To Participate In Upcoming Investor Conferences

(MENAFN- GlobeNewsWire - Nasdaq) CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM;“Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today announced its participation in the following upcoming investor conferences:

• Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the TD Cowen 46th Annual Healthcare Conference on Tuesday, March 3, 2026, at 1:10 p.m. ET.
• Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the 2026 Leerink Global Healthcare Conference on Tuesday, March 10, 2026, at 4:20 p.m. ET.

Webcasts of the fireside chats will be available under the Events and Presentations section of the Company's investor relations website at .

About Cullinan Therapeutics

Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company developing potential first- or best-in-class, high-impact therapies for autoimmune diseases and cancer. Cullinan pursues promising therapeutic targets while leveraging core expertise in T cell engagers, which are established in oncology and are now advancing into autoimmune diseases. With a clinical-stage pipeline built on a rigorous scientific approach and purposeful innovation, Cullinan is advancing its mission to deliver new standards of care for patients. Learn more about Cullinan at , and follow Cullinan on LinkedIn and X.

Contacts:

Investors
Nick Smith
+1 401.241.3516
...

Media
Rose Weldon
+1

MENAFN24022026004107003653ID1110781849